Diabetes mellitus (DM) remains an important predictor for mortality in patients with ST-segment Elevation Myocardial Infarction (STEMI) although the use of reperfusion therapy has resulted in a considerable improvement of survival. Of importance, newly diagnosed diabetic patients and those with fasting glycaemia in the diabetes range have even worse outcomes compared to patients with known diabetes. Overall, 50% of all patients presenting with STEMI have abnormal glucose metabolism of which fewer than 50% are known diabetics. Obviously, the efficacy of reperfusion therapy in reopening the occluded artery is similar in STEMI patients with or without impaired fasting glycaemia, while the pre-existing decreased myocardial perfusion in STEMI patients with impaired fasting glycaemia persists after successful epicardial revascularisation.
There is no doubt that improving microvascular perfusion within the ischaemic myocardium remains the ultimate goal of managing STEMI patients with impaired glucose metabolism. Identification of defective myocardial perfusion together with an aggressive antithrombotic regimen, reduction of the inflammatory response of the ischaemic myocardium and improvement of glycaemia control represent promising therapeutic approaches that deserve additional specific clinical investigations. This review examines all these important issues.
1. Malmberg K, Norhammar A, Wedel H, Ryden L.Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Circulation1999;99:2626–32.
2.
2. Zeller M, Cottin Y, Brindisi MC et al.The RICO survey working group. Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J2004;25:308–12.
3.
3. Mak KH, Moliterno DJ, Granger CB et al.Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries. J Am Coll Cardiol1997;30:171–9.
4.
4. Timmer JR, van der Horst IC, Ottervanger JP et al.Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur Heart J2005;25:926–31.
5.
5. American Diabetes Association.Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26:S5–S20.
6.
6. Suleiman M, Hammerman H, Boulos M et al.Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction. A prospective study. Circulation2005;111:754–60.
7.
7. Wahab NN, Cowden EA, Pearce NJ et al.Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?. J Am Coll Cardiol2002;40:1748–54.
8.
8. Van de Werf F, Ardissino D, Betriu A et al.Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2003;24:28–66.
9.
9. Fibrinolytic Therapy Trialists (FTT) Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1, 000 patients. Lancet1994;343:311–22.
10.
10. Pfeffer MA, Moye LA, Braunwald E et al.Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266:528–32.
11.
11. Barron HV, Bowlby LJ, Breen T et al.Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation1998;97:1150–6.
12.
12. Vaur L, Danchin N, Hanania G et al.Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey. Diabetes Metab2003;29:241–9.
13.
13. Mahaffey KW, Granger CB, Toth CA et al.Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded coronary arteries. J Am Coll Cardiol1997;30:1606–10.
14.
14. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD.Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol1993;22:1433–7.
15.
15. Eagle KA, Goodman SG, Avezum A et al.Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet2002;359:373–7.
16.
16. Creager MA, Lüscher TF.Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part I. Circulation2003;108:1527–32.
17.
17. Simes RJ, Topol EJ, Holmes DR Jr et al.Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation1995;91:1923–8.
18.
18. Woodfield SL, Lundergan CF, Reiner JS et al.Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol1996;28:1661–9.
19.
19. Ohman EM, Califf RM, Topol EJ et al.Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation1990;82:781–91.
20.
20. Angeja BG, de Lemos J, Murphy SA et al.Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J2002;144:649–56.
21.
21. The GUSTO Investigators.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med1993;329:673–82.
22.
22. Keeley EC, Boura JA, Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet2003;361:13–20.
23.
23. Silber S, Albertsson P, Aviles FF et al.Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J2005;26:804–47.
24.
24. Timmer JR vdHI, de Luca G, Ottervanger JP et al.Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction versus without diabetes mellitus. Am J Cardiol2005;95:1375–7.
25.
25. Prasad A, Stone GW, Stuckey TD et al.Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol2005;45:508–14.
26.
26. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA.Impaired nitric oxide-mediated vasodilation in noninsulin-dependent diabetes. J Am Coll Cardiol1996;27:567–74.
27.
27. Yokoyama I, Momomura S-I, Ohtake T et al.Reduced myocardial reserve in noninsulin-dependent diabetes mellitus. J Am Coll Cardiol1997;30:1472–7.
28.
28. Kawaguchi M, Techigawara M, Ishihata T et al.A comparison of ultra-structural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels1997;12:267–74.
29.
29. Ishihara M, Inoue I, Kawagoe T et al.Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol2001;38:1007–11.
30.
30. Lind L, Fugmann A, Branth S et al.The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin. Clin Sci (London)2000;99:169–74.
31.
31. Gresele P, Guglielmini G, De Angelis M et al.Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol2003;41:1013–20.
32.
32. Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, Mc-Donagh PF.Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complicat2000;14:96–107.
33.
33. Iwakura K, Ito H, Ikushima M et al.Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol2003;41:1–7.
34.
34. Grines CL, Topol EJ, Califf RM et al.The TAMI Group. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. Circulation1989;80:245–53.
35.
35. Gibson CM, Schömig A.Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation2004;109:3096–105.
36.
36. Gibson M, Cannon CP, Murphy SA et al.Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation2002;105:1909–15.
37.
37. Ren J, Gintant GA, Miller RE et al.High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol1997;273:H2876–H2883.
38.
38. Ceriello A.Acute hyperglycaemia: a new risk factor during myocardial infarction. Eur Heart J2005;26:328–31.
39.
39. Dibra A, Mehilli J, Dirschinger J et al.Thrombolysis In Myocardial Infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol2003;41:925–9.
40.
40. Timmer JR, Ottervanger JP, de Boer MJ et al.Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol2005;45:999–1002.
41.
41. Roffi M, Chew DP, Mukherjee D et al.Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation2001;104:2767–71.
42.
42. Roffi M, Moliterno DJ, Meier B et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention. Do Tirofiban and ReoPro give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up. Circulation2002;105:2730–6.
43.
43. De Luca G, Suryapranata H, Stone GW et al.Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. JAMA2005;293:1759–65.
44.
44. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA2004;292:362–6.
45.
45. Antoniucci D, Rodriguez A, Hempel A et al.A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol2003;42:1879–85.
46.
46. Montalescot G, Barragan P, Wittenberg O et al.Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med2001;344:1895–903.
47.
47. Neumann FJ, Kastrati A, Schmitt C et al.Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol2000;35:915–21.
48.
48. Sabatine MS, Cannon CP, Gibson CM et al.Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med2005;352:1179–89.
49.
49. Iakovou I, Schmidt T, Bonizzoni E et al.Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA2005;293:2126–30.
50.
50. Hansen TK, Thiel S, Wouters PJ et al.Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab2003;88:1082–8.
51.
51. van der Horst IC, Zijlstra F, van't Hof AW et al.Zwolle Infarct Study Group. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose insulin-potassium study: a randomized trial. J Am Coll Cardiol2003;42:784–91.
52.
52. Cerello A.Acute hyperglycaemia: a ‘new’ risk factor during myocardial infarction. Eur Heart J2005;26:328–31.
53.
53. Oliver MF, Opie LH.Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet1994;343:155–8.
54.
54. Malmberg K, Ryden L, Wedel H et al.Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J2005;26:650–61.
55.
55. The CREATE-ECLA Trial Group Investigators.Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. JAMA2005;293:437–46.
56.
56. Marfella R, Siniscalchi M, Esposito K et al.Effects of stress hyperglycemia on acute myocardial infarction. Diabetes Care2003;26:3129–35.
57.
57. Zhang C, Yang J, Jennings LK.Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated vascular non-leukocyte-derived reactive oxygen species. Diabetes Care2004;53:2950–9.
58.
58. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M.Association between hyper- and hypoglycemia and 2-year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J2005;26:1255–61.
59.
59. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L.Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J2003;24:838–44.
60.
60. Granger CB, Mahaffey KW, Weaver WD et al.Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation2003;108:1184–90.
